

# Externally Funded Research Projects


Susan Burkhill, Iain Gardner

Simcyp Limited (a Certara Company), Blades Enterprise Centre, John Street, Sheffield, S2 4SU, UK



## Summary

- Simcyp involvement in European grants started in 2004 with BioSim (an FP6 funded project)
- Participation in funded research collaborations has ↑ since 2007
- FP6, FP7 & IMI International Collaborative Projects have given €1,349,869 since 2004
- Other Funded Research Projects: £496,431 since 2002



Overview of the funds received from grant funding bodies (FP 6 & 7, IMI & TSB)

## Ongoing grant projects

2012 – 2017  IMI  
**'Oral Biopharmaceutics Tool'**

Aims to develop and validate novel, innovative and integrated experimental and theoretical models and methods that will significantly improve prediction accuracy of *in vivo* drug product performance. The project and its consortium have been designed to advance the capabilities within the European Pharma Industry for prediction of the complex human GI drug absorption mechanisms & to implement these new models and methods in industrial drug development settings.


2011 – 2016  **Drug Disease Model Resources** IMI  
**'Drug Disease Model Resources'**


Aims to develop common definition language for data, models and workflows, along with an ontology based standard for storage and transfer of models and associated metadata. A drug and disease model library will be developed as a public resource.


2011 – 2015  FP7  
**'Treat Infections in Neonates 2'**

Aims to evaluate azithromycin, included in the EMEA priority list of therapeutic areas that need specific drug evaluation, in preterm and term neonates.

2011 – 2015  FP7  
**'Treatment of Adrenal Insufficiency in Neonates'**  
Aims to develop a neonatal formulation of hydrocortisone.

2012 – 2014  **'A User-Friendly Tool for Analysis of Complex In Vitro Experimental Data in Drug Discovery and Development'**  
Aims to develop a user-friendly software tool for analysis of *in vitro* data describing the metabolism, transport and receptor binding of drugs.

2010 – 2013  FP7  
**'Neuroscience on Barriers in Development'**  
Aims to understand the BBB in the developing brain along with improving the understanding of neurological disorders of infancy & those in adults with developmental antecedents and develop novel drug delivery strategies to the brain for large molecules.

2008 – 2013  FP7  
**'Profiling the Toxicity of New Drugs: A Non Animal-Based Approach Integrating Toxicodynamics and Biokinetics'**  
Aims to develop strategies to improve the assessment of drug safety in the early stage of development and late discovery phase in a rapid and cost effective manner by an intelligent combination of non animal-based test systems, cell biology, mechanistic toxicology and *in silico* modelling

2013 – 2014  National Institutes of Health  
**'Mechanisms of Drug Disposition during Pregnancy'**



2012 – 2017 **CRADA**  
**'Development of Physiologically-Based Pharmacokinetic (PBPK) Dog Models to Support Veterinary Drug Evaluations'**



2012 – 2017  
**'Improved In Vitro to In Vivo Extrapolation in Chemical Safety Risk Assessment of Human Systemic Toxicity'**



PhD Studentships & Industrial Fellowships

2013 – 2016 **MRC CASE Studentship**  
**'Dose Optimisation in Paediatric Oncology using Physiologically-Based Pharmacokinetic Models'**



Simcyp Contact for more information:

Jennifer Bonner

2012 – 2016 **MRC CASE Studentship**  
**'Assessment of Parameters for Quantitative Predictions of DDIs Arising from Induction of Metabolising Enzymes and Transporters'**



Simcyp Contact for more information:

Lisa Almond

2011 – 2014 **Royal Commission Funded Studentship**  
**'The Impact of Inter-Individual Variability in Human Intestinal Transport Protein Abundance and Function on Drug Absorption'**



Simcyp Contact for more information:

Matthew Harwood